Cellectar Biosciences, Inc. Annual Report - How They Did This Year

Curious about Cellectar Biosciences, Inc.'s recent performance or considering an investment? This summary translates their latest annual report for the fiscal year ended December 31, 2025, into plain English, providing a clear overview of the company's activities and financial standing.

Business Overview

Cellectar Biosciences is a clinical-stage biopharmaceutical company. It focuses on developing novel phospholipid drug conjugates (PDCs), a type of targeted therapy, for cancer treatment. Their proprietary PDC platform selectively delivers therapeutic agents to cancer cells, minimizing harm to healthy tissue.

PCLX-001, their lead product candidate, is currently in advanced clinical trials for various blood cancers, including multiple myeloma and diffuse large B-cell lymphoma (DLBCL). In fiscal year 2025, the company primarily advanced PCLX-001 through its Phase 2b clinical trial, achieving key enrollment milestones and preparing for potential pivotal studies. Cellectar also continued preclinical work on its earlier-stage pipeline candidates. Overall, 2025 marked a year of significant clinical execution and strategic pipeline development. As expected for a company at this stage, it did not include major regulatory approvals or commercial launches.

Financial Performance

As a clinical-stage biotech, Cellectar generated minimal revenue of approximately $0.8 million for fiscal year 2025, primarily from research grants and collaboration agreements. This slight increase from the prior year reflects ongoing grant funding.

The company reported a net loss of $42.5 million for the year, an increase from $38.0 million in the prior year. This reflects substantial investment in research and development (R&D) activities. R&D expenses rose to $38.2 million in 2025 from $32.5 million in 2024, primarily due to increased clinical trial costs and manufacturing scale-up for PCLX-001. General and administrative expenses also modestly increased. This net loss aligns with expectations for a company focused on clinical development rather than commercial sales.

As of June 30, 2025, regular investors (non-affiliates) held approximately $12.8 million in common stock. By February 24, 2026, the company had 4,240,129 shares of common stock outstanding.

Cellectar is a "Smaller reporting company," meaning it has a relatively smaller market capitalization and revenue compared to larger public companies. This designation often brings:

• Different reporting requirements.
• Potentially higher stock volatility.
• Lower stock liquidity.

Therefore, investors should carefully understand the company's specific financial situation and pipeline progress.

Risk Factors

Investing in biotech carries inherent risks. Key risks for Cellectar Biosciences include:

• Clinical Trial Failures: PCLX-001 or other pipeline candidates may not demonstrate sufficient efficacy or safety in ongoing or future clinical trials, severely impacting the company's prospects.
• Regulatory Approval Uncertainty: Even with positive trial data, FDA or other regulatory body approval is not guaranteed, and the approval process can be lengthy and unpredictable.
• Need for Additional Funding: The company will require significant additional capital to complete clinical development and commercialize its products. This could lead to further stock dilution for existing shareholders or an inability to continue operations.
• Competition: The oncology market is highly competitive. Other companies may develop more effective or safer treatments, or reach the market sooner.
• Intellectual Property: Challenges to their patents or an inability to obtain new patents could impact their market position and ability to protect their technology.
• Manufacturing and Supply Chain: Potential issues with manufacturing partners or supply chain disruptions could delay drug development, clinical trials, or future commercialization.
• Reliance on Key Personnel: The loss of key scientific or management personnel could adversely affect the company's operations and ability to execute its strategy.

Management Discussion and Analysis (MD&A) Highlights

Management's discussion for 2025 highlighted key operational achievements and financial considerations.

Operational Highlights:

• PCLX-001 Clinical Progress: The company successfully completed patient enrollment for the dose expansion portion of the Phase 2b trial for PCLX-001 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer. This marked a critical milestone.
• Orphan Drug Designation: Cellectar received Orphan Drug Designation from the FDA for PCLX-001 for a specific rare cancer indication. This designation could provide market exclusivity, tax credits, and accelerate development.
• Preclinical Data: The company presented promising preclinical data for a new pipeline candidate, PCLX-002, at a major scientific conference, indicating potential for future development and pipeline expansion.

Financial and Operational Challenges:

• Increased R&D Costs: Higher-than-anticipated costs associated with clinical trial operations and manufacturing scale-up contributed to the higher net loss. Management views these expenses as critical investments for future potential.
• Patient Enrollment Delays: The company experienced minor patient enrollment delays in one of its smaller trials, slightly pushing back expected data readouts. Management indicated these delays were manageable and did not significantly impact the lead program's overall timeline.
• Capital Needs: Continued reliance on external financing to fund operations remains a key challenge, potentially leading to future shareholder dilution. Management actively explores various financing options.

Leadership and Strategy: In 2025, the executive leadership team and Board of Directors remained stable, providing strategic continuity. However, the company refined its clinical strategy for PCLX-001, focusing more intensely on specific DLBCL patient sub-populations that showed the most promising early data. This aims to accelerate a path to potential approval and optimize resource allocation.

Market Trends and Regulatory Environment: Management discussed operating within a dynamic environment shaped by several trends:

• Growth in Targeted Therapies: The strong industry and regulatory push for more targeted cancer therapies aligns well with Cellectar's PDC platform.
• Orphan Drug Incentives: Continued government incentives for developing rare disease treatments benefit companies like Cellectar with Orphan Drug Designations.
• Personalized Medicine: The increasing focus on personalized medicine and biomarker-driven drug development could create opportunities for PCLX-001 if specific patient populations respond particularly well.
• Pricing and Reimbursement Pressures: Broader healthcare trends in drug pricing and reimbursement could impact future market access and profitability, especially for novel therapies.
• Advances in Oncology: Rapid advancements in oncology research create a constantly evolving competitive landscape requiring continuous innovation.

Financial Health

How is the company's financial health? As of December 31, 2025, Cellectar held $28.7 million in cash and cash equivalents. The company carries minimal long-term debt, primarily lease obligations. Based on its current burn rate, management estimates sufficient cash to fund operations into the third quarter of 2026. To extend this runway and fund ongoing clinical trials, the company may need to raise additional capital through equity offerings or strategic partnerships soon. This is common for clinical-stage biotech companies, and management actively evaluates options to secure additional funding.

Future Outlook

What does the future hold for Cellectar Biosciences? For 2026, the company's key priorities include:

• Reporting top-line data from the Phase 2b DLBCL trial for PCLX-001 in mid-2026, which will be a critical inflection point for the program.
• Initiating discussions with regulatory authorities (e.g., FDA) regarding the design of a potential pivotal Phase 3 trial for PCLX-001, contingent on positive Phase 2b data.
• Advancing PCLX-001 into additional indications, such as pediatric cancers, based on encouraging preclinical data and unmet medical needs.
• Continuing preclinical development of PCLX-002 and other earlier-stage PDC candidates to expand the pipeline.
• Actively exploring strategic partnerships or collaborations to support further development and potential commercialization of PCLX-001 and other assets.

Competitive Position

Cellectar operates in the highly competitive oncology therapeutic area, specifically within blood cancers. Its primary competitors include larger pharmaceutical companies and other biotech firms developing treatments for multiple myeloma, DLBCL, and other solid tumors. These competitors often possess greater financial, technical, and human resources.

Cellectar aims to differentiate itself through its proprietary phospholipid drug conjugate (PDC) platform. This platform selectively delivers therapeutic agents to cancer cells while minimizing harm to healthy tissue. This targeted approach could offer safety and efficacy advantages over conventional chemotherapy or less targeted therapies, potentially improving patient outcomes and carving out a strong competitive niche. The company believes its unique mechanism of action and early clinical data support its potential to address significant unmet needs in difficult-to-treat cancers.